Literature DB >> 23897602

Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals.

Susan L Davis1, Marc H Scheetz, John A Bosso, Debra A Goff, Michael J Rybak.   

Abstract

STUDY
OBJECTIVES: To describe the implementation of vancomycin dosing and monitoring practices recommended by the consensus guidelines in a diverse sample of hospitals, and to identify needs for quality improvement and research.
DESIGN: Cross-sectional study using an online survey instrument.
SETTING: Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Research Network. PARTICIPANTS: A total of 163 respondents from MAD-ID who work in antimicrobial stewardship and represent unique hospitals.
MEASUREMENTS AND MAIN RESULTS: The survey population represented a wide range of patient populations (96% adult, 49% pediatric, and 23% long-term care) and settings (52% not-for-profit nonuniversity, 31% university based, and 11% for profit). Automatic consultation of pharmacy services for all vancomycin dosing was reported in 51% of the institutions. Among the dosing and monitoring practices endorsed by the consensus guidelines, participant institutions commonly followed these recommendations: use of trough concentrations without peak concentrations, maintenance of trough concentration higher than 10 mg/L, and target trough concentrations of 15-20 mg/L for complicated infections. In contrast, there was less consistent application of appropriate timing of trough concentrations, use of loading doses, and use of actual body weight. The remaining challenges and controversies surrounding vancomycin dosing are discussed.
CONCLUSION: Despite the availability of consensus guideline recommendations, practices for dosing and monitoring of vancomycin are not universally applied. The findings of this survey highlight many opportunities for future research and quality improvement strategies.
© 2013 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  Vancomycin; clinical pharmacy services; survey; therapeutic drug monitoring

Mesh:

Substances:

Year:  2013        PMID: 23897602     DOI: 10.1002/phar.1327

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  21 in total

1.  Vancomycin-Associated Acute Kidney Injury in a Large Veteran Population.

Authors:  Geeta Gyamlani; Praveen K Potukuchi; Fridtjof Thomas; Oguz Akbilgic; Melissa Soohoo; Elani Streja; Adnan Naseer; Keiichi Sumida; Miklos Z Molnar; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Am J Nephrol       Date:  2019-01-24       Impact factor: 3.754

2.  Elevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis.

Authors:  Reza Zonozi; Aozhou Wu; Jung-Im Shin; Alex Secora; Josef Coresh; Lesley A Inker; Alex R Chang; Morgan E Grams
Journal:  Mayo Clin Proc       Date:  2019-01       Impact factor: 7.616

Review 3.  Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

Authors:  Frieder Keller; Bernd Schröppel; Ulla Ludwig
Journal:  World J Nephrol       Date:  2015-07-06

4.  A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.

Authors:  John P Prybylski
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

5.  Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

Authors:  Anthony M Casapao; Susan L Davis; Viktorija O Barr; Kenneth P Klinker; Debra A Goff; Katie E Barber; Keith S Kaye; Ryan P Mynatt; Leah M Molloy; Jason M Pogue; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.

Authors:  Joseph J Carreno; Ben Lomaestro; John Tietjan; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 7.  Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Authors:  Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

8.  Vancomycin: Audit of American guideline-based intermittent dose administration with focus on overweight patients.

Authors:  Mari Koyanagi; Rebecca Anning; Mark Loewenthal; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2020-01-22       Impact factor: 4.335

9.  The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).

Authors:  Thomas P Lodise; Susan L Rosenkranz; Matthew Finnemeyer; Scott Evans; Matthew Sims; Marcus J Zervos; C Buddy Creech; Pratish C Patel; Michael Keefer; Paul Riska; Fernanda P Silveira; Marc Scheetz; Richard G Wunderink; Martin Rodriguez; John Schrank; Susan C Bleasdale; Sara Schultz; Michelle Barron; Ann Stapleton; Dannah Wray; Henry Chambers; Vance G Fowler; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

10.  Optimization of time to initial vancomycin target trough improves clinical outcomes.

Authors:  Anthony P Cardile; Christopher Tan; Michael B Lustik; Amy N Stratton; Cristian S Madar; Jun Elegino; Günther Hsue
Journal:  Springerplus       Date:  2015-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.